{
  "id": "5e44c76f48dab47f26000022",
  "type": "yesno",
  "question": "Is Aptiganel effective for treatment of stroke?",
  "ideal_answer": "No. Aptiganel is not efficacious in patients with acute ischemic stroke and may be harmful.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12917902",
    "http://www.ncbi.nlm.nih.gov/pubmed/12365832",
    "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
    "http://www.ncbi.nlm.nih.gov/pubmed/12849400"
  ],
  "snippets": [
    {
      "text": "Trends for increased mortality with three NMDA antagonists were seen - selfotel (OR 1.19 [0.81-1.74]), aptiganel (OR 1.32 [0.91-1.93]) and gavestinel (OR 1.12 [0.95-1.32]) - but this did not achieve significance for the NMDA antagonists considered as a class (1.09 [0.96-1.23]). Aptiganel was also associated with a trend towards worse functional outcome (OR 1.20 [0.88-1.65]) although this was not the case for either of the other two compounds.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12917902",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No improvement in clinical outcome of stroke has been seen with competitive NMDA antagonists (selfotel) and non-competitive NMDA antagonists (dextrorphan, GV150526, aptiganel and eliprodil).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12365832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glutamate N-methyl-D-aspartate (NMDA) receptor antagonists (competitive receptor antagonists, ion channel blockers, and glycine antagonists)--such as selfotel, aptiganel, eliprodil, licostinel and gavestinel--failed to show efficacy in clinical trials of stroke or traumatic brain injury. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12849400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P =.31). At 7 days, placebo-treated patients exhibited slightly greater neurological improvement on the NIH Stroke Scale than high-dose aptiganel patients (mean improvement for placebo group, -0.8 points vs for high-dose aptiganel, 0.9 points; P =.04). The mortality rate at 120 days in patients treated with high-dose aptiganel was higher than that in patients who received placebo (26.3% vs 19.2%; P =.06).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful. The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\n\nAptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P =.31).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glutamate N-methyl-D-aspartate (NMDA) receptor antagonists (competitive receptor antagonists, ion channel blockers, and glycine antagonists)--such as selfotel, aptiganel, eliprodil, licostinel and gavestinel--failed to show efficacy in clinical trials of stroke or traumatic brain injury.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12849400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glutamate N-methyl-D-aspartate ( NMDA ) receptor antagonists ( competitive receptor antagonists , ion channel blockers , and glycine antagonists)--such as selfotel , aptiganel , eliprodil , licostinel and gavestinel--failed to show efficacy in clinical trials of stroke or traumatic brain injury",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12849400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No improvement in clinical outcome of stroke has been seen with competitive NMDA antagonists ( selfotel ) and non-competitive NMDA antagonists ( dextrorphan , GV150526 , aptiganel and eliprodil",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12365832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P =.31).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There was no improvement in outcome for either aptiganel (low-dose or high-dose) group compared with the placebo group at 90 days (median Modified Rankin Scale score for all 3 treatment groups = 3; P =.31).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11730442",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}